List of principal authors. Preface. <strong>Section I: Bile acid synthesis.</strong> <strong>1.</strong> Species differences in bile acid metabolism; A.F. Hofmann, et al. <strong>2.</strong> Role of alternative pathways of bile acid biosynthesis in liver disease; J. Sjövall. <strong>3.</strong> Regulation of bile acid synthesis; Z.R. Vlahcevic, et al. <strong>Section II: Bile acid transport.</strong> <strong>4.</strong> Hepatocellular basolateral bile acid uptake proteins; B. Hagenbusch, et al. <strong>5.</strong> Transcellular bile acid transport; J.M. Crawford. <strong>6.</strong> Bile acid transport across the canalicular membrane; D. Keppler, et al. <strong>7.</strong> The hepatic Na<sup>+</sup> taurocholate cotransporter is downregulated in experimental models of cholestasis; C. Gartung, J.L. Boyer. <strong>Section</strong> <strong>III: New concepts of bile acid-induced hepatotoxicity and bile</strong> <strong>secretion. 8.</strong> Effect of bile salts on biomembranes; S. Güldütuna, et al. Apoptosis - an alternative mechanism of bile salt hepatotoxicity; T. Patel, et al. <strong>10.</strong> Bile acids and hepatocellular signalling; U. Beuers, et al. <strong>11.</strong> Hepatobiliary cholesterol secretion and the function of mdr2 P-glycoprotein; R.P.J. Oude Elferink, et al. <strong>Section IV: Bile secretory function of liver and</strong> <strong>bile duct cells.</strong> <strong>12.</strong> Vesicle targeting to the canalicular domain regulates bile acid transport and bile secretory function in the liver; J.L. Boyer, et al. <strong>13.</strong> Effects of bile acids on bile duct epithelial cells; M. Strazzabosco, et al. <strong>14.</strong> Increased biliary secretion of phospholipids in primary sclerosing cholangitis: another mechanism of action of ursodeoxycholic acid? A. Stiehl, et al. <strong>15.</strong> Bile acid transport systems as pharmaceutical targets: bile acid-derived HMG-CoA reductase inhibitors; W. Kramer, et al. <strong>Section</strong> <strong>V: Ursodeoxycholic acid treatment in cholestatic liver diseases.</strong> <strong>16.</strong> Long-term experience with ursodeoxycholic acid for patients with biliary cirrhosis and primary sclerosing cholangitis. <strong>17.</strong> State of the Art Lecture: Ursodeoxycholic acid in cholestatic liver diseases &endash; clinical efficiency and putative mechanism of action; R. Poupon. Index.
